Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating reissued by Seaport Global Securities in a report issued on Friday, MarketBeat.com reports. They currently have a $16.00 price objective on the biotechnology company’s stock. Seaport Global Securities’ price objective would indicate a potential upside of 178.75% from the stock’s previous close.
Several other analysts have also recently issued reports on CNAT. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $10.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $16.17.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 5.74 on Friday. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The company’s 50 day moving average price is $5.56 and its 200 day moving average price is $5.85. The company’s market cap is $172.22 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $9.33 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. On average, equities analysts expect that Conatus Pharmaceuticals will post ($0.45) EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its position in Conatus Pharmaceuticals by 641.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after acquiring an additional 949,785 shares in the last quarter. Vanguard Group Inc. boosted its position in Conatus Pharmaceuticals by 31.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after acquiring an additional 239,373 shares in the last quarter. State Street Corp bought a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $2,092,000. Northern Trust Corp boosted its position in Conatus Pharmaceuticals by 640.6% during the 2nd quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after acquiring an additional 257,030 shares in the last quarter. Finally, Numeric Investors LLC bought a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $1,620,000. 33.13% of the stock is currently owned by institutional investors and hedge funds.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.